Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Characterization and optimization of single dose, thermostable and durable vaccine platform towards increased clinical acceptance

Award Number: R01AI179898
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/23/2024
PERIOD OF PERFORMANCE END DATE: 12/31/2024

Group Awards By:

View Award Description

Characterization and optimization of single dose, thermostable and durable vaccine platform towards increased clinical acceptance - SUMMARY/ABSTRACT Broadening the spectrum of vaccine platforms that confer protective, durable and broad immunogenicity is important for pandemic preparedness. Here, we aim to create essential preclinical data to characterize a novel genetic vaccine platform called PARVAX to increase its clinical acceptance. Our previous studies show that a single dose of PARVAX candidates for COVID-19 elicits sustained humoral immunity, near-sterilizing upper and lower airway protection from a SARS-CoV-2 challenge, and potent and durable cellular responses. These qualities combined with established commercial and low-cost manufacturing processes, make this platform imminently feasible, scalable and affordable for vaccine applications. In this proposal, we will investigate the mechanism behind the potency and durability of PARVAX, which we hypothesize is correlated with antigen expression kinetics (Aim 1). We also use rational engineering approaches to enhance the potency of the PARVAX platform, which will enhance safety and applicability for other pathogens (Aim 2). Finally, we propose to generate proof of the potency of PARVAX as a vaccine platform beyond COVID-19 by exploring the serum and mucosal immunity and protection from influenza viruses in two preclinical models of influenza infection (Aim 3). The proposed work is highly relevant for pandemic preparedness, since it will enable the rapid design of new and preclinically derisked PARVAX candidates for existing and future pathogens, and has the potential to provide clarity on the means to improve the durability, breadth and mucosal immunity of other platforms.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = -$668,569 )
2026	2024	SCHEPENS EYE RESEARCH INSTITUTE, INC., THE	20 STANIFORD ST	BOSTON	MA	02114	SUFFOLK	USA	Allergy and Infectious Diseases Research	000	1	12/3/2025	NEW	-$668,569
														Subtotal = -$668,569

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2024	SCHEPENS EYE RESEARCH INSTITUTE, INC., THE	20 STANIFORD ST	BOSTON	MA	02114	SUFFOLK	USA	Allergy and Infectious Diseases Research	000	1	9/23/2025	NEW	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $668,569 )
2024	2024	SCHEPENS EYE RESEARCH INSTITUTE, INC., THE	20 STANIFORD ST	BOSTON	MA	02114	SUFFOLK	USA	Allergy and Infectious Diseases Research	000	1	8/23/2024	NEW	$604,137
2024	2024	SCHEPENS EYE RESEARCH INSTITUTE, INC., THE	20 STANIFORD ST	BOSTON	MA	02114	SUFFOLK	USA	Allergy and Infectious Diseases Research	001	1	9/13/2024	NEW	$64,432
														Subtotal = $668,569

Grand Total All Awards = $0

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Characterization and optimization of single dose, thermostable and durable vaccine platform towards increased clinical acceptance

Award Number: R01AI179898

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/23/2024

PERIOD OF PERFORMANCE END DATE: 12/31/2024

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer